The Tories make drug policy a central campaign issue, while the other parties are quietly backing harm reduction
Author Archives: Alexandra Keeler
Alexandra Keeler is a Toronto-based reporter focused on covering mental health, drugs and addiction, crime and social issues. Alexandra has more than a decade of freelance writing experience.
Study links B.C.’s drug policies to more overdoses, but researchers urge caution
A study links B.C.’s safer supply and decriminalization to more opioid hospitalizations, but experts note its limitations
Addiction experts demand witnessed dosing guidelines after pharmacy scam exposed
Delays in new guidelines frustrate addiction experts, who call for improved efforts to wean clients from prescribed opioids
Why psychedelic therapy is stuck in the waiting room
There is mounting evidence of psychedelics’ effectiveness at treating mental disorders. But researchers face obstacles conducting rigorous studies
This opioid addiction medication saves lives. So why has uptake been slow?
Sublocade, a powerful medication to treat opioid addiction, is poised to become more accessible. But rapid access is only part of the solution
Should fentanyl dealers be charged with manslaughter for fatal overdoses?
Police are charging more drug dealers with manslaughter in fentanyl overdose deaths. But the shift is not satisfying everyone
How Ottawa’s border security plan falls short
Experts say Canada’s border security investments target physical borders, when crime groups’ methods increasingly bypass them altogether
B.C. overhauls safer supply in response to widespread pharmacy scam
The B.C. government is returning to a model of witnessed safer supply, after a leaked investigation showed pharmacies exploiting drug users for profits
Canada cracks down on precursor chemicals to battle fentanyl crisis
Health Canada launches two new drug detection units to fight fentanyl trafficking—but will they be enough?
Does America’s ‘drug czar’ hold lessons for Canada?
The US has had a drug czar for decades. Experts share how this position has shaped US drug policy—and what it could mean for Canada
